Financhill
Sell
43

ARGX Quote, Financials, Valuation and Earnings

Last price:
$577.25
Seasonality move :
11.35%
Day range:
$575.41 - $583.16
52-week range:
$377.47 - $678.21
Dividend yield:
0%
P/E ratio:
35.39x
P/S ratio:
14.42x
P/B ratio:
6.42x
Volume:
297.4K
Avg. volume:
411.6K
1-year change:
48.81%
Market cap:
$35.3B
Revenue:
$2.2B
EPS (TTM):
$16.33

Price Performance History

Performance vs. Valuation Benchmarks

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Competitors

Company Revenue Forecast Earnings Forecast Revenue Growth Forecast Earnings Growth Forecast Analyst Price Target Median
ARGX
argenx SE
$840M $2.33 82.69% 496.99% $761.17
GNFT
Genfit SA
$151.2M -- -- -- $8.70
NCNA
NuCana PLC
-- -$0.01 -- -99.69% $104.00
NVO
Novo Nordisk AS
$11.9B $0.92 19.3% 36.74% $91.54
PHG
Koninklijke Philips NV
$4.6B $0.14 3.5% -45.61% $31.77
TRIB
Trinity Biotech PLC
$7.5M -$0.57 8.81% -25.13% --
Company Price Analyst Target Market Cap P/E Ratio Dividend per Share Dividend Yield Price / LTM Sales
ARGX
argenx SE
$577.89 $761.17 $35.3B 35.39x $0.00 0% 14.42x
GNFT
Genfit SA
$4.10 $8.70 $205M 32.57x $0.00 0% 2.84x
NCNA
NuCana PLC
$0.11 $104.00 $695.9K -- $0.00 0% --
NVO
Novo Nordisk AS
$79.83 $91.54 $354.7B 23.64x $1.14 2.08% 8.16x
PHG
Koninklijke Philips NV
$22.75 $31.77 $21B 50.44x $0.97 4.25% 1.11x
TRIB
Trinity Biotech PLC
$0.67 -- $12.5M -- $0.00 0% 0.13x
Company Total Debt / Total Capital Beta Debt to Equity Quick Ratio
ARGX
argenx SE
-- 0.297 -- 6.40x
GNFT
Genfit SA
-- -0.565 -- --
NCNA
NuCana PLC
-- -3.655 -- --
NVO
Novo Nordisk AS
46.15% 1.812 5.59% 0.54x
PHG
Koninklijke Philips NV
39.29% 0.773 34.81% 0.69x
TRIB
Trinity Biotech PLC
147.47% -1.550 785.94% 0.87x
Company Gross Profit Operating Income Return on Invested Capital Return on Common Equity EBIT Margin Free Cash Flow
ARGX
argenx SE
$709.9M $141.2M 18.03% 21.33% 25.74% -$147M
GNFT
Genfit SA
-- -- -- -- -- --
NCNA
NuCana PLC
-- -$3.5M -- -- -- -$4M
NVO
Novo Nordisk AS
$9.2B $5.5B 53.78% 84.88% 54.06% $1.4B
PHG
Koninklijke Philips NV
$1.9B $163.1M 2.17% 3.18% 4.54% -$1.2B
TRIB
Trinity Biotech PLC
$5.3M -$2.2M -45.03% -- -11.29% -$6.3M

argenx SE vs. Competitors

  • Which has Higher Returns ARGX or GNFT?

    Genfit SA has a net margin of 21.43% compared to argenx SE's net margin of --. argenx SE's return on equity of 21.33% beat Genfit SA's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    ARGX
    argenx SE
    89.78% $2.58 $5.5B
    GNFT
    Genfit SA
    -- -- --
  • What do Analysts Say About ARGX or GNFT?

    argenx SE has a consensus price target of $761.17, signalling upside risk potential of 31.72%. On the other hand Genfit SA has an analysts' consensus of $8.70 which suggests that it could grow by 112.26%. Given that Genfit SA has higher upside potential than argenx SE, analysts believe Genfit SA is more attractive than argenx SE.

    Company Buy Ratings Hold Ratings Sell Ratings
    ARGX
    argenx SE
    14 1 0
    GNFT
    Genfit SA
    1 0 0
  • Is ARGX or GNFT More Risky?

    argenx SE has a beta of 0.390, which suggesting that the stock is 61.003% less volatile than S&P 500. In comparison Genfit SA has a beta of 1.148, suggesting its more volatile than the S&P 500 by 14.837%.

  • Which is a Better Dividend Stock ARGX or GNFT?

    argenx SE has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Genfit SA offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. argenx SE pays -- of its earnings as a dividend. Genfit SA pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios ARGX or GNFT?

    argenx SE quarterly revenues are $790.7M, which are larger than Genfit SA quarterly revenues of --. argenx SE's net income of $169.5M is higher than Genfit SA's net income of --. Notably, argenx SE's price-to-earnings ratio is 35.39x while Genfit SA's PE ratio is 32.57x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for argenx SE is 14.42x versus 2.84x for Genfit SA. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    ARGX
    argenx SE
    14.42x 35.39x $790.7M $169.5M
    GNFT
    Genfit SA
    2.84x 32.57x -- --
  • Which has Higher Returns ARGX or NCNA?

    NuCana PLC has a net margin of 21.43% compared to argenx SE's net margin of --. argenx SE's return on equity of 21.33% beat NuCana PLC's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    ARGX
    argenx SE
    89.78% $2.58 $5.5B
    NCNA
    NuCana PLC
    -- -$0.63 --
  • What do Analysts Say About ARGX or NCNA?

    argenx SE has a consensus price target of $761.17, signalling upside risk potential of 31.72%. On the other hand NuCana PLC has an analysts' consensus of $104.00 which suggests that it could grow by 90413.49%. Given that NuCana PLC has higher upside potential than argenx SE, analysts believe NuCana PLC is more attractive than argenx SE.

    Company Buy Ratings Hold Ratings Sell Ratings
    ARGX
    argenx SE
    14 1 0
    NCNA
    NuCana PLC
    0 1 0
  • Is ARGX or NCNA More Risky?

    argenx SE has a beta of 0.390, which suggesting that the stock is 61.003% less volatile than S&P 500. In comparison NuCana PLC has a beta of 1.240, suggesting its more volatile than the S&P 500 by 23.98%.

  • Which is a Better Dividend Stock ARGX or NCNA?

    argenx SE has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NuCana PLC offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. argenx SE pays -- of its earnings as a dividend. NuCana PLC pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios ARGX or NCNA?

    argenx SE quarterly revenues are $790.7M, which are larger than NuCana PLC quarterly revenues of --. argenx SE's net income of $169.5M is higher than NuCana PLC's net income of -$3.1M. Notably, argenx SE's price-to-earnings ratio is 35.39x while NuCana PLC's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for argenx SE is 14.42x versus -- for NuCana PLC. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    ARGX
    argenx SE
    14.42x 35.39x $790.7M $169.5M
    NCNA
    NuCana PLC
    -- -- -- -$3.1M
  • Which has Higher Returns ARGX or NVO?

    Novo Nordisk AS has a net margin of 21.43% compared to argenx SE's net margin of 37.18%. argenx SE's return on equity of 21.33% beat Novo Nordisk AS's return on equity of 84.88%.

    Company Gross Margin Earnings Per Share Invested Capital
    ARGX
    argenx SE
    89.78% $2.58 $5.5B
    NVO
    Novo Nordisk AS
    83.49% $0.92 $37.3B
  • What do Analysts Say About ARGX or NVO?

    argenx SE has a consensus price target of $761.17, signalling upside risk potential of 31.72%. On the other hand Novo Nordisk AS has an analysts' consensus of $91.54 which suggests that it could grow by 14.67%. Given that argenx SE has higher upside potential than Novo Nordisk AS, analysts believe argenx SE is more attractive than Novo Nordisk AS.

    Company Buy Ratings Hold Ratings Sell Ratings
    ARGX
    argenx SE
    14 1 0
    NVO
    Novo Nordisk AS
    4 5 1
  • Is ARGX or NVO More Risky?

    argenx SE has a beta of 0.390, which suggesting that the stock is 61.003% less volatile than S&P 500. In comparison Novo Nordisk AS has a beta of 0.662, suggesting its less volatile than the S&P 500 by 33.759%.

  • Which is a Better Dividend Stock ARGX or NVO?

    argenx SE has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Novo Nordisk AS offers a yield of 2.08% to investors and pays a quarterly dividend of $1.14 per share. argenx SE pays -- of its earnings as a dividend. Novo Nordisk AS pays out 43.71% of its earnings as a dividend. Novo Nordisk AS's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

  • Which has Better Financial Ratios ARGX or NVO?

    argenx SE quarterly revenues are $790.7M, which are smaller than Novo Nordisk AS quarterly revenues of $11B. argenx SE's net income of $169.5M is lower than Novo Nordisk AS's net income of $4.1B. Notably, argenx SE's price-to-earnings ratio is 35.39x while Novo Nordisk AS's PE ratio is 23.64x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for argenx SE is 14.42x versus 8.16x for Novo Nordisk AS. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    ARGX
    argenx SE
    14.42x 35.39x $790.7M $169.5M
    NVO
    Novo Nordisk AS
    8.16x 23.64x $11B $4.1B
  • Which has Higher Returns ARGX or PHG?

    Koninklijke Philips NV has a net margin of 21.43% compared to argenx SE's net margin of 1.86%. argenx SE's return on equity of 21.33% beat Koninklijke Philips NV's return on equity of 3.18%.

    Company Gross Margin Earnings Per Share Invested Capital
    ARGX
    argenx SE
    89.78% $2.58 $5.5B
    PHG
    Koninklijke Philips NV
    45.13% $0.08 $20.9B
  • What do Analysts Say About ARGX or PHG?

    argenx SE has a consensus price target of $761.17, signalling upside risk potential of 31.72%. On the other hand Koninklijke Philips NV has an analysts' consensus of $31.77 which suggests that it could grow by 39.63%. Given that Koninklijke Philips NV has higher upside potential than argenx SE, analysts believe Koninklijke Philips NV is more attractive than argenx SE.

    Company Buy Ratings Hold Ratings Sell Ratings
    ARGX
    argenx SE
    14 1 0
    PHG
    Koninklijke Philips NV
    1 1 0
  • Is ARGX or PHG More Risky?

    argenx SE has a beta of 0.390, which suggesting that the stock is 61.003% less volatile than S&P 500. In comparison Koninklijke Philips NV has a beta of 0.763, suggesting its less volatile than the S&P 500 by 23.719%.

  • Which is a Better Dividend Stock ARGX or PHG?

    argenx SE has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Koninklijke Philips NV offers a yield of 4.25% to investors and pays a quarterly dividend of $0.97 per share. argenx SE pays -- of its earnings as a dividend. Koninklijke Philips NV pays out -0.14% of its earnings as a dividend.

  • Which has Better Financial Ratios ARGX or PHG?

    argenx SE quarterly revenues are $790.7M, which are smaller than Koninklijke Philips NV quarterly revenues of $4.3B. argenx SE's net income of $169.5M is higher than Koninklijke Philips NV's net income of $80M. Notably, argenx SE's price-to-earnings ratio is 35.39x while Koninklijke Philips NV's PE ratio is 50.44x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for argenx SE is 14.42x versus 1.11x for Koninklijke Philips NV. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    ARGX
    argenx SE
    14.42x 35.39x $790.7M $169.5M
    PHG
    Koninklijke Philips NV
    1.11x 50.44x $4.3B $80M
  • Which has Higher Returns ARGX or TRIB?

    Trinity Biotech PLC has a net margin of 21.43% compared to argenx SE's net margin of -31.41%. argenx SE's return on equity of 21.33% beat Trinity Biotech PLC's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    ARGX
    argenx SE
    89.78% $2.58 $5.5B
    TRIB
    Trinity Biotech PLC
    35.03% -$0.46 $55.5M
  • What do Analysts Say About ARGX or TRIB?

    argenx SE has a consensus price target of $761.17, signalling upside risk potential of 31.72%. On the other hand Trinity Biotech PLC has an analysts' consensus of -- which suggests that it could grow by 2137.8%. Given that Trinity Biotech PLC has higher upside potential than argenx SE, analysts believe Trinity Biotech PLC is more attractive than argenx SE.

    Company Buy Ratings Hold Ratings Sell Ratings
    ARGX
    argenx SE
    14 1 0
    TRIB
    Trinity Biotech PLC
    0 0 0
  • Is ARGX or TRIB More Risky?

    argenx SE has a beta of 0.390, which suggesting that the stock is 61.003% less volatile than S&P 500. In comparison Trinity Biotech PLC has a beta of 0.840, suggesting its less volatile than the S&P 500 by 15.99%.

  • Which is a Better Dividend Stock ARGX or TRIB?

    argenx SE has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Trinity Biotech PLC offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. argenx SE pays -- of its earnings as a dividend. Trinity Biotech PLC pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios ARGX or TRIB?

    argenx SE quarterly revenues are $790.7M, which are larger than Trinity Biotech PLC quarterly revenues of $15.2M. argenx SE's net income of $169.5M is higher than Trinity Biotech PLC's net income of -$4.8M. Notably, argenx SE's price-to-earnings ratio is 35.39x while Trinity Biotech PLC's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for argenx SE is 14.42x versus 0.13x for Trinity Biotech PLC. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    ARGX
    argenx SE
    14.42x 35.39x $790.7M $169.5M
    TRIB
    Trinity Biotech PLC
    0.13x -- $15.2M -$4.8M

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

Is Palantir Stock Overvalued?
Is Palantir Stock Overvalued?

By every traditional yardstick, including a price‑to‑sales well above 100,…

Is Gamestop’s Bitcoin Strategy Going To Succeed?
Is Gamestop’s Bitcoin Strategy Going To Succeed?

When GameStop (NYSE: GME) announced in Q1 that its board had…

How High Will Roku Stock Go?
How High Will Roku Stock Go?

Streaming software and hardware maker Roku (NASDAQ:ROKU) has seen its…

Stock Ideas

Buy
65
Is MSFT Stock a Buy?

Market Cap: $3.5T
P/E Ratio: 40x

Buy
57
Is NVDA Stock a Buy?

Market Cap: $3.5T
P/E Ratio: 48x

Sell
39
Is AAPL Stock a Buy?

Market Cap: $2.9T
P/E Ratio: 32x

Alerts

Sell
11
VEON alert for Jun 14

VEON [VEON] is down 18.57% over the past day.

Buy
74
DAVE alert for Jun 14

Dave [DAVE] is down 12.68% over the past day.

Buy
54
DAR alert for Jun 14

Darling Ingredients [DAR] is up 9.12% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock